This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Southwest Oncology Group (SWOG). Clinical trials include:

1. Docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2 positive, stage IV breast cancer. S0215

2. Phase III trial of continuous schedule AC + G versus q 2-week schedule AC, followed by paclitaxel given either q 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy in node-positive or high-risk node-negative breast cancer. S0221

3. Phase III randomized trial of anastrozole versus anastrozole and fulves-trant as first line therapy for postmenopausal women with metastatic breast cancer. S0226

4. Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer. S0230

5. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. S0307

6. Phase II trial of simple oral therapy (continuous oral cyclophosphamide and capecitabine) in patients with metastatic breast cancer. S0430

7. A phase II study of goserelin plus anastrozole for the treatment of male patients with hormone-receptor positive metastatic or recurrent breast cancer. S0511

8. Randomized placebo-controlled biomarker modulation trial using celecoxib in premenopausal women at high risk for breast cancer. Phase IIb. S0300

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by West Midlands Breast Group (WMBG). Clinical trials include:

1. aTTom – adjuvant Tamoxifen Treatment – offer more?

2. Sequencing of chemotherapy and radiotherapy in adjuvant breast cancer. SECRAB

3. A phase III randomized trial of gemcitabine in paclitaxel-containing, epirubicin-based, adjuvant chemotherapy for women with early stage breast cancer. tAnGo

4. Tamoxifen and Exemestane Adjuvant Multicentre trial TEAM

5. Neoadjuvant trial of preoperative exemestane or letrozole ± celecoxib in the treatment of ER positive postmenopausal early breast cancer NEO-EXCEL

6. A neoadjuvant study of sequential epirubicin + cyclophosphamide and paclitaxel ± gemcitabine in the treatment of high risk early breast cancer with molecular profiling, proteomics and candidate gene analysis. Neo-tAnGo

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by West German Study Group (WSG). Clinical trials include:

1. WSG and AGO-Mamma Intergroup Study: Randomized phase III trial of EC-Doc: adjuvant chemotherapy of breast carcinoma with 1–3 positive lymph nodes. (AM02)

2. WSG Study: Randomized phase III trial of adjuvant CEF/TAC chemotherapy +/− Darbepoetin alfa for patients with primary breast cancer and more than 3 positive axillary lymph nodes. ARA Plus (AM03)

3. ICE – Study: Ibandronate with or without capecitabine in elderly patients with early breast cancer. BIG 4-04 / GBG 32. (see also description under GBG)

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Yorkshire Breast Cancer Research Group (YBCRG). Clinical trials include:

1. Does adjuvant zoledronic acid reduce recurrence in patients with high risk localized breast cancer? – The AZURE Trial. BIG 1-04

2. Cost-effective use of BISphosphonates in metastatic bone disease: A comparison of bone MARKer directed zoledronic acid therapy to a standard schedule – The BISMARK Trial.